Median progression free survival in the selpercatinib group was not reached and was 16.8 months in the cabozantinib/vandetanib group. The Food and Drug Administration ...
If you have a certain thyroid or lung cancer, your doctor may prescribe Retevmo for you. It’s a prescription drug that’s used to treat the following cancers in specific situations: With advanced ...
The approvals were based on data from the LIBRETTO-001 trial. The Food and Drug Administration (FDA) has granted accelerated approval to Retevmo ® (selpercatinib) for adults with locally advanced or ...
Retevmo (selpercatinib, formerly known as LOXO-292) (pronounced reh-TEHV-moh) is a highly selective and potent RET kinase inhibitor with CNS activity. Retevmo may affect both tumor cells and healthy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback